The clinical updates provide long-term value potential, especially in HCC and metabolic indications, but near-term fundamentals are deteriorating. The $4.3M in recent financing extends runway, but continued losses and low revenue may pressure the stock. Traders should monitor upcoming Phase 3 data readouts and any partnership developments.
Price Chart
Executive Summary
Can-Fite BioPharma reported its 2025 financial results, showing a 40% year-over-year decline in revenue to $0.41 million and a widening net loss to $9.83 million, driven by higher R&D and administrative expenses. Despite the weak financials, the company highlighted significant clinical progress, including a pancreatic cancer trial meeting safety endpoints, a 9-year complete response in an HCC patient, and IP expansion into metabolic diseases.
Key Financial Metrics
Key Facts
- Revenue for 2025 was $0.41 million, down 40% from $0.67 million in 2024
- Net loss increased to $9.83 million in 2025 from $7.88 million in 2024
- R&D expenses rose 16.26% to $6.69 million, primarily due to advancement of Piclidenoson and Namodenoson trials
- Cash and equivalents increased to $8.54 million as of December 31, 2025, up from $7.88 million in 2024
- On March 4, 2026, the company received $4.3 million in gross proceeds from warrant exercises and inducement
- Namodenoson achieved a 9-year complete response in an advanced HCC patient and showed promise as a bridge to liver transplant
- Company expanded Namodenoson's potential into obesity and metabolic diseases with new patent allowances
Financial Impact
Revenue down $260K YoY; net loss increased by $1.95M; R&D and G&A expenses rose significantly; cash position improved to $8.54M after $4.3M in warrant proceeds
Risk Factors
- Sustained revenue decline and increasing losses may raise concerns about viability
- Heavy reliance on clinical trial outcomes with no near-term commercial products
- Dilution risk from future financings despite recent warrant proceeds
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263128 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.95 | awaiting T+5 | — | $1.68 (−13.85%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.68 (+13.85%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.68 (+13.85%) |
Sep 14, 2026 6w ago | EFFECT | $2.30 $2.22 | ▲ +3.48% | ▲ +3.58% | $1.68 (+26.96%) |
Sep 9, 2026 6w ago | 6-K | $2.19 $2.24 | ▲ +2.28% | ▲ +3.38% | $1.68 (−23.29%) |
Sep 3, 2026 7w ago | 6-K | $2.35 $2.33 | ▼ −0.85% | ▲ +0.30% | $1.68 (−28.51%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.68 (−28.81%) |
Sep 2, 2026 7w ago | Press Release | $2.36 $2.16 | ▲ +8.47% | ▲ +7.52% | $1.68 (+28.81%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.68 (−28.81%) |
Aug 17, 2026 10w ago | 6-K | $3.58 $3.35 | ▼ −6.42% | ▼ −5.23% | $1.68 (−53.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers